Dermatology

The approval of secukinumab is the second approved biologic to treat hidradenitis suppurativa.

Recognizing that skin diseases such as atopic dermatitis, psoriasis, and hidradenitis suppurativa present differently in skin of color can prevent delays in diagnosis and treatment, explained James Song, MD, director of clinical research and associate chief medical officer at Frontier Dermatology.

Lauren Miller, PA-C, kicked off the inaugural 2023 Inflammatory Disease Summit by discussing the psychosocial impacts related to atopic dermatitis, psoriasis, and hidradenitis suppurativa.

During a recent Institute for Value-Based Medicine® event, speakers discussed the use of immunotherapy and targeted therapy to treat melanoma and managing the toxicities of these treatments.

A European Academy of Dermatology and Venereology study explored the pathway from dermatologic consult to diagnosis to treatment and outcomes in the health care system.

For patients who had 12 months of continuous health care coverage before and after receiving a diagnosis of vitiligo, treatment rates were at suboptimal levels.

There are many immunotherapy-caused skin toxicities, but most can be easily managed.

Sexual and gender minority (SGM) patients with chronic inflammatory skin diseases (CSIDs) may be disproportionately influenced by cost and noncost obstacles to health care.

Lisa Kottschade, RN, CNP, FAPO, a nurse practitioner at Mayo Clinic, discussed immune-related adverse events and biomarkers in relation to melanoma treatment.

A survey indicated that truncal acne may negatively impact adolescents’ and young adults’ quality of life and self-perception.

Meredith McKean, MD, MPH, the associate director of the Sarah Cannon Research Institute's Melanoma and Skin Cancer Research Program at Tennessee Oncology, discussed new melanoma studies and treatment developments.

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with adalimumab alone.

Hidradenitis suppurativa (HS) may involve skin or nerve ending changes that could lead to peripheral neuropathy and changes in the transduction of specific stimuli.

No significant differences in resistance were observed against participants with acne vulgaris (AV) against 7 antibiotics.

Fecal microbiota profiles were observed to be significantly different among patients with melanoma and controls, as well as those with early-stage and late-stage melanoma.

Hidradenitis suppurativa (HS) in elderly patients is not unusual and may be associated with male sex, study suggests.

Hidradenitis suppurativa (HS) contributes to an extensive weakening in work ability and productivity, as well as large loss of gross value added.

Variants associated with hidradenitis suppurativa (HS) near the SOX9 and KLF5 genes were associated with HS risk.

Researchers conducted systematic mapping of relevant digital health intervention literature to determine the impact of these interventions on dermatologic care outcomes.

The presence of sex differences in immunological functioning influences hidradenitis suppurativa (HS).

Studies showed the various treatments improved symptoms, but more trials need to be done.

Genetic variants associated with hidradenitis suppurativa (HS) were identified, although a causal effect is not proven.

More understanding of the physical, psychological, and economic burdens of hyperhidrosis is needed.

Study finds that use of mHealth app could be useful in early detection of skin cancer but cautions that overdiagnosis is a possibility.

A possible association between hidradenitis suppurativa (HS) with chronic kidney disease (CKD) suggests that patients with HS who present signs of CKD should be assessed by a nephrologist, suggests a study.